Lexicon Pharmaceuticals Stock Surges 10% on Bullish Cantor Fitzgerald Initiation

Lexicon Pharmaceuticals (NASDAQ: LXRX) shares surged by double digits after Wall Street firm Cantor Fitzgerald initiated coverage with a highly bullish outlook, citing significant potential in the company's late-stage cardiovascular drug pipeline. The stock climbed 10.0% in mid-day trading, sharply outperforming a negative broader market.

Cantor Fitzgerald's Bullish Thesis

Analyst Steve Seedhouse of Cantor Fitzgerald started coverage on Lexicon with an "Overweight" rating and a 12-month price target of $8.00. This target implies substantial upside from the stock's recent trading levels, which were near $2.00.

The firm's positive thesis is centered on sotagliflozin, Lexicon's dual SGLT1/2 inhibitor. The analyst highlighted the drug's potential as a treatment for hypertrophic cardiomyopathy (HCM), which is being evaluated in a pivotal late-stage clinical trial.

Key Catalyst Ahead

The initiation comes at a crucial time for the company. Its Phase 3 SONATA-HCM trial for sotagliflozin has now completed enrollment, surpassing its original target of 500 patients across more than 130 sites in 20 countries.

Ad

This sets the stage for a major clinical catalyst, with topline data from the trial now anticipated in the first quarter of 2027. According to Cantor Fitzgerald, sotagliflozin's existing approval as INPEFA for heart failure helps support the drug's broader cardiovascular profile ahead of the HCM data readout.

Market Reaction

The analyst's endorsement triggered a significant, company-specific rally, with shares reaching an intraday high of $2.05. The move represents a continued recovery from a 52-week low of $1.10 seen earlier in the year.

The stock's sharp ascent stood in stark contrast to the wider market sentiment. During the same trading session, the S&P 500 was down 0.8%, the Dow Jones Industrial Average fell 0.7%, and the Nasdaq Composite declined 1.0%.